Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8229035 | 0.91 | GAA (0.59) | GAAMEN1KMT2AALDH1A1MAOB | |
| SCHEMBL8228824 | 0.91 | GAA (0.59) | GAAMEN1KMT2AALDH1A1MAOB | |
| SCHEMBL4261542 | 0.87 | GAA (0.66) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4267783 | 0.87 | GAA (0.66) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL4267387 | 0.86 | GAA (0.64) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL20527292 | 0.86 | GAA (0.64) | GAAMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL2273759 | 0.85 | KDM1A (0.55) | GAACHEK1MEN1KMT2AALDH1A1 | |
| SCHEMBL2761932 | 0.84 | SPHK1 (0.57) | GAAOPRK1OPRM1OPRD1MAOB | |
| SCHEMBL4274161 | 0.84 | GAA (0.71) | GAAMEN1KMT2AMAOB | |
| SCHEMBL12639839 | 0.84 | HRH3 (0.56) | MEN1KMT2AALDH1A1RAB9ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579356-B2 | Thia-tetraazaacenaphthylene kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | claimed |
| US-7427625-B2 | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-23 | — | — | US | claimed |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-15 | — | — | US | claimed |
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | claimed |
| WO-2007092879-A2 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | WO | claimed |
| WO-2006118749-A1 | THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-09 | — | — | WO | claimed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-7579356-B2 | Thia-tetraazaacenaphthylene kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| US-20080300264-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | CONNOLLY PETER J | 2008-12-04 | — | — | US | disclosed |
| US-7427625-B2 | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-23 | — | — | US | disclosed |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007092879-A2 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2006118749-A1 | THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | MAP3K11, MAP3K6, MAP4K2 | GAA 2069/4885CHEK1 202/4885MEN1 2186/4885 |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | ADK, MAP3K9, MAP4K5 | GAA 679/4885CHEK1 439/4885MEN1 4404/4885 |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | GAA 2002/4885CHEK1 2237/4885MEN1 1049/4885 |
| US-20080300264-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | MAP3K11, MAP3K6, MAP4K2 | GAA 2069/4885CHEK1 202/4885MEN1 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.